European Drug Regulator To Consider Expanded Use Of Novo Nordisk's Wegovy Weight-Loss Drug
Portfolio Pulse from Vandana Singh
The European Medicines Agency (EMA) is considering the expanded use of Novo Nordisk's weight loss drug, Wegovy, to also reduce the risk of stroke and heart attacks. This follows positive results from the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (MACE) with Wegovy compared to placebo. Novo Nordisk's CEO highlighted the drug's efficacy at the JPMorgan Healthcare conference. NVO shares were down 1.12% at $105.76 in the last check.
January 22, 2024 | 7:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's Wegovy is under EMA review for expanded use, which could potentially increase its market and usage in Europe. Despite positive trial results, NVO shares have dropped slightly.
The EMA's consideration of Wegovy for expanded use could lead to increased demand and integration into European public health systems, which would be positive for Novo Nordisk. However, the short-term impact on the stock is neutral to slightly positive, as the current share price has experienced a minor decline, possibly due to market conditions or profit-taking after the news.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90